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The pandemic novel influenza A (H1N1) infection was considered widespread in Brazil on July, 2009. Since then, 9.249 cases were 
confirmed in Brazil, most of them concentrated in São Paulo. The Hospital das Clínicas of the University of São Paulo is a refer-
ence center for H1N1 cases in São Paulo. The purpose of this review is to analyze the evidence concerning diagnosis, prevention, 
and treatment of novel influenza A (H1N1) infection. In addition, we propose guidelines for the management of this pandemic 
emphasizing Hospital das Clínicas “bundles” for the control of the pandemic novel influenza A (H1N1). 
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1. INTRODUCTION
In April 2009, the first two cases of human infection with 
a novel influenza A (H1N1) virus were reported in the United 
States.1 During the same period, an outbreak of respiratory 
infection was reported in Mexico.2 The virus was found to 
be an H1N1 virus that was antigenically and genetically 
unrelated to human seasonal influenza viruses and genetically 
related to viruses known to circulate in swine.3 In the ensuing 
weeks, the swine-origin influenza virus (S-OIV) H1N1 spread 
worldwide, constituting a pandemic, as defined by the World 
Health Organization.4 The novel H1N1 virus has distinct 
molecular properties of human, avian, and swine influenza, 
resulting from antigenic drift, which is the main cause of the 
seasonal epidemic of swine flu.4 
As of September 13, 2009, the S-OIV caused over than 
296.471 virologically confirmed human cases and at least 
3.486 deaths in countries worldwide.5 Almost five months 1016
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after the description of the first cases, the pandemic S-OIV 
infection continues to spread globally, presents a high rate 
of transmission among humans, and can lead to serious 
complications and mortality. The purpose of this guideline 
is to review the evidence concerning diagnosis, prevention, 
and treatment of S-OIV infection. In addition, we emphasize 
the Hospital das Clínicas’ plan for the management of 
the pandemic novel influenza A (H1N1). This report is an 
initiative from the “Cabinet Crisis” - a group of healthcare 
professionals at the Hospital das Clínicas da Faculdade de 
Medicina da Unversidade de São Paulo who continuously 
evaluate the “bundles” for control of S-OIV infection, 
meaning the groups of interventions and advertisements, to 
obtain better outcomes in the management of this disease.
2. HISTORICAL ASPECTS 
An estimated 58% of the 1407 human pathogens are 
zoonotic, which means that they normally occur in animals 
but can also infect humans.6 The ability of a microorganism 
to cross the species barrier in association with a high 
transmissibility rate between humans may result in epidemics. 
The novel influenza A (H1N1) virus, which is responsible for 
the current pandemic, is derived from two unrelated swine 
viruses, one of which is a derivative of the 1918 human virus.3 
The notorious 1918 pandemic of influenza A (H1N1), the 
Spanish flu, was derived from an avian source and caused 50 
million deaths.6 Some authors proposed that the virus resided 
in an avian reservoir and affected humans either directly upon 
exposure to birds or through an intermediate host.7 As the 
1918 influenza virus can replicate and cause disease in swine, 
scientists believe that it has continued to circulate in swine 
and this fact would facilitate the genetic reassortment between 
different influenza virus strains.8 
A practical way to think about influenza A events over the 
past 91 years is to recognize that we are living in a pandemic 
era that began in 1918. The novel H1N1 virus associated with 
the ongoing 2009 pandemic is a fourth-generation descendant 
of the 1918 virus. The complex evolutionary history of this 
virus combines unique structural properties and genetic 
mixing among human viruses and avian and swine-adapted 
influenza viruses.9 Two features of the influenza virus explain 
its ability to cause widespread disease. One is the high error 
rate during genomic replication.9,10 The other is the segmented 
influenza virus genome, which allows reassortment between 
different viral strains.9,10 Because of this continual change 
phenomenon, a seemingly endless variety of new viruses with 
potentially new properties are continuously being engineered. 
In contrast, this new virus is not only infecting humans 
and causing some disease, but it is also being transmitted 
efficiently from human to human. 
3. EPIDEMIOLOGY 
The pandemic novel influenza A (H1N1) infection was 
considered as widespread in Brazil on July 16.11 Since 
then, the Ministry of Health in Brazil, as suggested by the 
World Health Organization, has maintained a continuous 
epidemiologic vigilance of cases of acute respiratory 
syndrome (ARS). The strategy of vigilance considers any 
persons with flu syndrome as potential cases of influenza 
A (H1N1) and designates these individuals as presenting 
acute respiratory syndrome patients with cough, dyspnea, 
and fever. 
Until now, 46.810 cases of ARS were reported notified in 
Brazil.12 Of these, 9.249 (20%) patients presented infection 
with S-OIV or influenza A (H1N1). Seasonal influenza A 
infection was confirmed in 1.152 (2.5%) patients.11 
The observed age distribution is unusual and differs 
from seasonal influenza, being skewed towards younger age 
groups. There is a marked underrepresentation of infections 
in persons over 65 years of age, who make up only 2% of 
the reported cases. In Brazil, among the reported cases, the 
affected individuals tend to be young, with a median age of 
26 years. Most patients are 15-49 years of age. Considering 
the gender distribution, 57.5% of the confirmed cases of 
novel virus influenza A (H1N1) occur in women.11,12.
 Among these 9.249 confirmed cases in Brazil, 899 
deaths are reported with mortality rate of 0,47/per 100.000 
inhabitants.11 All Brazilian states have reported cases of 
S-OIV infection, with the exception of Sergipe. Most 
cases and deaths are concentrated in São Paulo, but major 
mortality rate was observed in Paraná (2,08/ 100.000 
inhabitants). 
As of September 12, 2009, 13.069 cases of ARS were 
registered in São Paulo and 3.733 are due to novel influenza 
A (H1N1) infection.11 São Paulo state registers 40.3% (3.733 
of 9.249) of all confirmed cases from Brazil, the majority 
identified in the city. 
The Hospital das Clínicas of Faculdade de Medicina 
da Universidade de São Paulo (HC-FMUSP) is the largest 
tertiary health care hospital in Brazil, with 6 medical 
institutes and other associated hospitals, and is a reference 
center for H1N1 cases in São Paulo. Three months after the 
report of the first case of novel H1N1 infection in Brazil, 
the Hospital das Clínicas has accumulated experience with 
about 1500 cases registered and 472 confirmed with a low 
lethality rate (7.14%).
The management of this disease requires specific 
knowledge and the expertise to provide an adequate 
diagnosis and treatment of patients. With the goal of 
obtaining better outcomes in diseased patients, the Hospital 
Council established a “Cabinet Crisis” to continuously 1017
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obtain information from Health Organs, Epidemiological 
Surveillance Systems and from literature regarding 
epidemiological data and clinical presentations of S-OIV 
infection and to provide an adequate structure for the care 
of patients. 
4. PATHOGENESIS
Influenza A,  B,  and  C  are  RNA  viruses  of  the 
Ortomyxoviridae family and cause both pandemic and 
seasonal disease in humans.14 Influenza A viruses are 
enveloped, single-stranded RNA viruses with a segmented 
genome. They are categorized into subtypes on the basis 
of the antigenic properties of the hemagglutinin (HA) and 
neuraminidase (NA) glycoproteins on the surface of the 
virus.14 The HA glycoprotein mediates attachment and entry 
of the virus on the cell surface and is the main target for 
immunity by neutralizing antibodies. The NA glycoprotein 
allows the spread of the virus by cleaving the glycosidic 
linkages to sialic acid on host cells and on the surface of 
the virus.15 Influenza A viruses are characterized according 
to their pathogenicity, which results in severe disease 
and death in different species. This S-OIV results from 
frequent antigenic changes (i.e., antigenic drift) due to point 
mutations and recombination events that occur during viral 
replication.15 The novel influenza A (H1N1) virus is not 
a new subtype, but because the large majority of humans 
appear to have no pre-existing antibodies to this virus, a 
substantial potential for widespread infection exists.14,15 
The novel influenza A (H1N1) virus has distinct 
properties that enable it to cause disease in both swine 
and humans and confers high rates of transmissibility 
among humans. The pathogenesis of human infection due 
to S-OIV is poorly understood, but appears to involve 
two phenomena: a) direct cytotoxic viral damage and b) a 
cytokine storm, resulting from the inflammatory response 
to viral infection.16,17 The interaction between host and 
virus may result in different forms of disease, depending 
on the viral load and the inflammatory response. In patients 
with co-morbidities, host mechanisms of defense may be 
defective and such patients can present an altered innate 
immune response. In the most severe cases, co-infection 
with other viruses and bacteria (Streptococcus pneumoniae, 
Haemophilus influenza, and Staphylococcus aureus) can 
occur contributing to the high rates of mortality.18
There is no evidence to date suggesting that the virus 
disseminates any differently from other human influenza 
viruses, i.e., by droplets from coughing and sneezing and 
direct and indirect contact with respiratory secretions from 
infected persons.19 An individual may sometimes become 
infected by touching something contaminated with flu 
viruses and then touching his or her mouth or nose.19 There 
is no evidence to suggest unusual transmission routes for 
influenza, and there is no reason to suggest transmission 
via food. Patients may be contagious from one day before 
developing symptoms to up to 7 days after they get sick.19,20 
Children and persons with deficient immunity might be 
contagious for longer periods of time.20 
5. CLINICAL FEATURES
Human infection with the novel virus influenza A 
(H1N1) is characterized by a variable clinical presentation. 
We can describe a spectrum of disease presentations: the 
asymptomatic form, “flu-like syndrome”, and the severe 
form with acute respiratory distress syndrome leading 
to death (Figure 1).21 The majority of patients present 
the “flu-like syndrome” with fever, myalgia, sore throat, 
arthralgia, cough, headache, chills, and fatigue.22,23 Fever is 
the most frequent symptom and usually lasts for three days. 
Respiratory symptoms generally disappear three or four days 
after the fever ends. Diarrhea, emesis, and weakness can be 
present in a significant number of cases.22,23
Despite the fact that in most patients the disease has 
a benign evolution and a limited duration, some patients 
may present respiratory failure, rapidly developing acute 
respiratory distress syndrome.24,25 Published data describe 
systemic disease and complications due to S-OIV infection 
such as:22,23 
a.  Worsening of previous existing disease
b.  Sinusitis, otitis, asthma
Figure 1 - Spectrum of novel influenza A (H1N1) infection1018
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c.  Pneumonia, acute lung injury, respiratory failure
d.  Pericarditis, myocarditis
e.  Myositis, rhabdomyolysis
f.  Acute renal failure due to acute tubular necrosis
g.  Encephalitis, seizures
h.  Systemic inflammatory response syndrome
i.  Multiple organ failure
j.  Death
The reported cases reveal that about 70% of patients who 
die or present severe forms of the disease have underlying 
conditions.22,23,24,25,26,27 Risk groups for hospitalization and 
severe disease due to S-OIV infection are: 
a.  Individuals with underlying chronic diseases: data show 
that most patients hospitalized due to the need for care 
present co-morbidities, such as: asthma, chronic obstruc-
tive airways disease, diabetes, immunocompromise, 
chronic cardiovascular disease, chronic renal failure, 
epilepsy, obesity, and cancer.22,23,24 
b.  Pregnant women: studies report that pregnant women 
infected with S-OIV have a four to five times greater 
chance of being hospitalized than healthy pregnant 
women and present more severe forms of the disease.25,26
c.  Young children: children under two years of age present 
high rates of hospitalization and death.27
d.  Older individuals: persons 65 years and older have a high 
likelihood of needing hospital care and exhibit a high 
case fatality rate.23,24
From these analyses we can describe a list of risk groups, 
i.e., groups that experience more severe infections than the 
general population (Figure 2).
Pregnant women have a potential for complicated 
disease. For that, in Hospital das Clínicas, there is a specific 
protocol of care for this group, which include hospital 
admission in suspected or confirmed cases with clinical 
complications and a careful vigilance system for mild forms 
of disease with home treatment. 
5.1 Hospital admission
To date, most human cases of new influenza A (H1N1) 
virus infection have exhibited an uncomplicated illness 
of limited duration. Hospitalization or antiviral therapy 
is therefore not likely to be required for most patients. 
Supportive care includes antipyretics, such as dypirone or 
acetaminophen for fever or pain, and fluid rehydration that 
can be provided as needed.22 
The specific risk factors that predict an increased risk of 
progressive disease are incompletely understood. Clinicians 
and caregivers should watch for signs of possible clinical 
deterioration (for example, difficulty breathing, chest pain, 
coughing up colored sputum, dyspnea, altered level of 
consciousness, and confusion) and refer immediately such 
patients to the hospital. Clinicians should also take into 
account any underlying co-morbidities, the already described 
risk groups (such as immunocompromising conditions, pre-
existing chronic lung or cardiovascular disease, diabetes, 
pregnancy, and young age). 
Patients who present one or more of the following signs 
and symptoms must be hospitalized in an intensive care unit:
a)  Hemodynamic instability 
b)  Acute respiratory failure
c)  Extensive lung compromise on chest X-ray
d)  Severe hypoxemia 
e)  An PO2/FiO2 < 300, characteristic of acute lung injury
f)   Compromise of other organs: acute renal failure, myosi-
tis, encephalitis, and other
g)  Organ dysfunction
5.2  Intensive care:
5.2.1 Ventilatory support: until now, there has been no 
unique, definite pattern of lung disease. Patients who present 
serious hypoxemia may present different forms of lung 
damage.23,24 Most patients present diffuse alveolar damage, 
but localized disease, bronchiolitis, lobar pneumonia, 
and pleural effusion may be present. Ventilator support 
indications will then depend on the clinical condition of the 
patients, evaluated through signs, symptoms, and laboratory 
analysis (including arterial gas). 
-  Non-invasive ventilation (NIV): despite the theoretical 
risk of aerosol production with this modality, we recom-
mend NIV in patients with hypoxemia due to the reduced 
rates of orotracheal intubation. Indications for and limi-
tations of this method in patients with S-OIV infection 
Figure 2 - Risk groups for S-OIV infection1019
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are the same as those for patients with respiratory failure 
due to other etiologies.28 NIV should be used in patients 
without hemodynamic instability or consciousness altera-
tions.28,29 The preferred modality is the BiPAP, with in-
spiratory pressure (IPAP) and expiratory pressure (EPAP) 
adjusted independently. After selecting and fitting the 
mask, the recommended initial settings are IPAP = 8-12 
cmH2O and EPAP = 3-5 cmH2O. The IPAP is increased 
gradually as tolerated, with the therapeutics goals of 
dyspnea relief, good patient-ventilator synchrony, and 
improved gas exchange. The EPAP may be increased as 
needed for alveolar recruitment. 
-  Invasive ventilation: 
-  Treatment of ARDS associated with new influenza A 
(H1N1) virus infection should be based on published ev-
idence-based guidelines for sepsis-associated ARDS.29,30 
Lung-protective mechanical ventilation strategies should 
be used. The rationale is not to cause damage of non-
affected areas. We recommend the following therapy:
a)  Ventilatory mode: most ARDS patients are ven-
tilated using conventional volume-cycled positive-
pressure ventilators. Most studies using low tidal 
volume for ARDS employed this mode.29,30 However, 
no differences in outcomes are detected if pressure-
controlled ventilation is chosen, since the low tidal 
volume strategy is reached. 
b)  Oxygen: treatment of hypoxemia in ARDS induced 
by H1N1 virus is almost always initiated using 100% 
oxygen (FIO2 = 1.0), and the concentration of O2 is 
reduced with the goal of maintaining a PaO2 greater 
than 60 mmHg (arterial O2 saturation of about 90%). 
The FIO2 should be lowered to less than 0.5 as soon 
as possible to reduce the risk of lung damage due to 
oxygen toxicity.
c)  Positive End-Expiratory Pressure (PEEP): Positive 
end-expiratory pressure works by counteracting the 
tendency toward alveoli collapse during pulmonary 
edema, low lung volume, and loss of surfactant.31 
In ARDS, the majority of the lung is atelectatic.29 
PEEP recruits partially collapsed areas, improving 
gas exchange.31 However, in some cases it is associ-
ated with barotrauma, pneumothorax, lung injury, 
inflammation, a cardiac output decrease, and shock.32 
Consequently, we recommend a PEEP level between 
5 and 12 cm H2O in most patients, and we can adjust 
the PEEP levels using a combination of the PV curve, 
the response of arterial blood gases, the hypothetical 
maximum and minimum PEEP values, and the hemo-
dynamic response. 
d)  Low-tidal-volume strategy: the most important 
development in the management of ARDS is that 
mechanical ventilation with a lower tidal volume 
than previously used is associated with an improved 
clinical outcome.29,30 This type of ventilation has been 
termed as the low-tidal volume or lung-protective 
strategy. The best risk:benefit ratio would be gained 
with a tidal volume of 6 ml/Kg or less, to reach a 
target plateau pressure of less than 30 cm H2O.30
e)  Recruitment maneuvers and the prone position: 
recruitment maneuvers and the prone position must 
be reserved for refractory hypoxemia, as in other 
cases of ARDS.33,34
5.2.2  Hemodynamic support: Patients admitted to 
the intensive care unit with S-OIV infection and ARDS 
may present shock. It is of main importance to maintain 
hemodynamic goals in these patients to avoid organ 
failure. Fluid management in this population should be 
performed carefully. Current evidence indicates that a net 
negative balance is desirable in ARDS.35 However, in these 
patients, hypovolemia must be avoided. Therefore, we 
recommend dynamic evaluation of the fluid status and a 
more conservative strategy for fluid replacement. In some 
cases, albumin associated with furosemide may offer benefit 
in the net balance.35,36 
Hemodynamic goals:
-  Mean arterial pressure > 65 mmHg
-  SVO2 > 70%
-  Lactate < 2 mmol/L
-   Diuresis higher than 1ml/Kg/h
For optimal tissue perfusion and to obtain adequate 
arterial pressure, it is often necessary to use vasopressors 
and inotropics. We suggest norepinephrine as the first-line 
vasopressor and dobutamine as the inotropic. Vasopressin 
should be reserved for refractory shock.37
5.2.3 Renal support: acute renal failure has been 
observed in patients with S-OIV infection, especially in 
cases presenting shock.22 The etiology of acute renal failure 
is usually acute tubular necrosis, and in such cases renal 
replacement therapy may be needed. 
5.2.4 Corticosteroids: controversy exists as to whether 
we should use high-dose corticosteroids in ARDS due to 
S-OIV infection.38 The positive effect would be a reduction 
of the inflammatory lung injury, potentially resulting in a 
better PO2/FIO2 ratio and less intubation, as in ARDS of 
other etiologies.39 The adverse events in influenza virus-
infected patients would be higher rates of opportunistic 
infection and, possibly, prolonged viral replication. We 1020
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do not have pathology data for H1N1 infection to guide 
the choice of therapy. So, we recommend the use of 
methylprednisolone (2 mg/Kg per day) just in cases of 
ARDS that do not response to initial measures.
Low doses of corticosteroids (hydrocortisone 50 mg IV 
four times per day) may be considered for patients in septic 
shock who require vasopressors and have suspected adrenal 
insufficiency. 
5.2.5 Antibiotics: antibiotic chemoprophylaxis should 
not be used. When pneumonia is present, treatment with 
antibiotics should follow the recommendations from 
published guidelines. However, seasonal influenza and past 
influenza pandemics have been associated with an increased 
risk of secondary Staphylococcus aureus infections, 
which may be severe, progress rapidly, have necrotizing 
effects, and, in some areas, may be caused by methicillin-
resistant strains.40 The results of microbiological studies, 
wherever possible, should be used to guide antibiotic usage 
for suspected bacterial coinfection in patients infected 
with the new influenza A (H1N1) virus. Several patients 
worldwide have developed community pneumoniae due 
to Streptococcus pneumoniae and Haemophilus influenza 
and ventilator-associated pneumonia or hospital-acquired 
pneumonia caused by typical nosocomial pathogens.41
5.2.6 Glycemic control: tight glucose control (< 140 mg/
dL) must be achieved in critically ill patients, according to 
the local protocol. This measure is associated with a decrease 
of morbidity and mortality in critical patients.42
5.2.7 Thromboembolic prophylaxis: patients infected 
with S-OIV should receive mechanical thromboprophylaxis 
and pharmacological if possible because, as critically ill 
patients with co-morbidities, they present a high risk for 
thromboembolic events. In a series of cases from Michigan, 
of 10 patients with S-OIV infection, five had a pulmonary 
embolism, although the higher incidence of thrombosis 
could be explained because seven were extremely obese 
(body mass index > 40).43 
6. DIAGNOSIS
Laboratory confirmation of the novel influenza A 
(H1N1) virus, especially at the beginning of a new 
community outbreak, or for unusual cases, has important 
implications for case management, consideration of antiviral 
treatment options, and avoidance of the inappropriate use of 
antibiotics.44 
Reverse transcriptase-polymerase chain reaction (RT-
PCR) will provide the most timely and sensitive evidence 
of infection with the novel influenza A (H1N1) virus.44,45 
Real-time RT-PCR is available in reference centers around 
the world.46 Samples for laboratory tests should be obtained 
from the deep nasal passages (nasal swab), nasopharynx 
(nasopharyngeal swab), or the bronchial aspirate if 
available.47 Upper respiratory tract sampling using a 
combination of nasal or nasopharyngeal and a throat swab 
is advised and may facilitate virus detection. It is not yet 
known which clinical specimen provides the best diagnostic 
yield for this specific infection.48 Specimen collection should 
be carried out with precautions since the procedure may 
expose the collector to respiratory secretions from infected 
patients. 
The real-time test through polymerase chain reaction, 
includes the use of specific primers and probes to diagnose 
S-OIV infection.46 The set of influenza primers and probes 
was created to detect:
(a)  Seasonal influenza A virus
(b)  Swine-origin influenza A virus
(c)  Novel virus influenza A (H1N1)
Currently, the data show that this method has a sensitivity 
of 99.3% and a specificity of 92.3% for the diagnosis of 
infection due to novel virus influenza A (H1N1).46 We 
recommend the following types of cases to be submitted for 
the test:
a)  patients who require hospitalization
b)  patients with risk factors for severe forms of disease
c)  patients in an individualized protocol – according to the 
clinical judgment
No validated rapid bedside diagnostic test is presently 
available to detect novel influenza A (H1N1) virus infection. 
As part of the HC “bundles” for control of novel H1N1 
infection, a real-time RT-PCR is available for patients and 
workers who fill criteria to be tested.
7. TREATMENT AND PROPHYLAXIS
The novel influenza A (H1N1) virus is currently 
susceptible  to  the  antiviral  medications  known  as 
neuraminidase inhibitors (NAIs), specifically oseltamivir 
and zanamivir.49,50 The virus is resistant to the adamantane 
medications amantadine or rimantadine.49 Clinical efficacy 
data on antiviral treatment are not yet available. Based on its 
in vitro susceptibility patterns and the clinical experiences 
derived from seasonal and avian influenza infection, early 
administration of NAIs might reduce the severity and 
duration of illness caused by the novel H1N1 virus infection 
and might also help to prevent progression to severe disease 
and death.51 Only sporadic cases of oseltamivir-resistant 
2009 influenza A (H1N1) viruses have been detected 1021
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worldwide, including nine cases in the United States.52 Eight 
of nine patients had a documented exposure to oseltamivir 
through either treatment or prophylaxis.52
Clinical judgment is an important factor in the treatment 
decision. People with suspected novel H1N1 influenza who 
present with an uncomplicated febrile illness typically do not 
require treatment unless they are at higher risk for influenza 
complications, and in areas with limited antiviral availability, 
local public health authorities might provide guidance about 
prioritizing treatment within groups at higher risk.53
Antiviral therapy may be beneficial, especially for the 
following groups:54 
1.  All hospitalized patients with confirmed, probable, or 
suspected novel influenza (H1N1).
2.  Patients who are at a higher risk for complications (listed 
above).
If used, antiviral treatment should ideally be initiated 
early, as soon as possible, but it may also be used at any 
stage of the active disease when ongoing viral replication 
is anticipated or documented. Evidence for the benefits 
of antiviral treatment in studies of seasonal influenza is 
highest when treatment is started within 48 hours of the 
onset of illness.55 However, studies investigating oseltamivir 
treatment of hospitalized patients have indicated a benefit, 
including reductions of mortality or duration of hospital 
stay, even for patients whose treatment was initiated after 
48 hours.56 
There are important pharmacological differences to 
consider when choosing NAIs for treatment. Oseltamivir is 
administered orally and provides a higher systemic level.57 
Zanamivir is delivered by oral inhalation, with low systemic 
absorption.57 Oseltamivir is the recommended treatment for 
lower respiratory tract complications.57 The recommended 
treatment duration is five days. In Brazil, oseltamivir is used 
for the treatment and prophylaxis of S-OIV infection (Tables 
1, 2 and 3). 
Rare neuropsychiatric symptoms, such as confusion or 
abnormal behavior, have occurred after beginning treatment 
for seasonal influenza with oseltamivir, particularly in 
children, but the contribution of oseltamivir to these events 
remains unknown.58 
Post-exposure antiviral chemoprophylaxis with either 
oseltamivir or zanamivir for 10 days can be considered for 
the following situations:59 
1.  Close contact of cases (confirmed, probable, or suspect-
ed) who are at a high risk for influenza complications
2.  Health care personnel, public health workers, or first 
responders who have had a recognized, unprotected 
close contact exposure to a person with novel (H1N1) 
influenza virus infection during the patient’s infectious 
period. 
In patients presenting renal failure, with a creatinine 
clearance between 10 and 30 ml/min/m2, a 50% dosage 
reduction of oseltamivir is recommended.60 There are no 
data available on the ideal dosage during renal replacement 
therapy. Patients with hepatic failure do not require dosage 
correction.60
Zanamivir is indicated for the treatment of influenza in 
adults and children (>5 years).57 The recommended dose 
for treatment of adults and children older than 5 years of 
age is two inhalations (2 x 5mg) twice daily for 5 days. 
Table 1 - Recommended antiviral treatment and prophylaxis for novel influenza A (H1N1) infection
Treatment Chemoprophylaxis
Oseltamivir Oseltamivir
Adults 75-mg capsule twice per day for 5 days 75-mg capsule once per day for 10 days
Children ≥ 12 months 15 kg or less 60 mg per day divided into 2 doses 30 mg once per day
16-23 kg 90 mg per day divided into 2 doses 45 mg once per day
24-40 kg 120 mg per day divided into 2 doses 60 mg once per day
>40 kg 150 mg per day divided into 2 doses 75 mg once per day
Table 2 - Recommended antiviral treatment for children 
younger than 1 year using oseltamivir
Age Recommended treatment for 5 days
<3 months 12 mg twice daily
3-5 months 20 mg twice daily
6-11 months 25 mg twice daily
Table 3 - Recommended antiviral chemoprophylaxis for 
children younger than 1 year using oseltamivir
Age Recommended prophylaxis for 10 days
<3 months Not recommended unless the situation is judged as 
critical
3-5 months 20 mg once daily
6-11 months  25 mg once daily1022
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Inhaled zanamivir has been temporally associated with 
bronchospasm, and patients with preexisting airway disease 
appear to be at an increased risk for this severe adverse 
reaction.57
Available products in Brazil:
(a) Tamiflu® Roche – 75-mg capsule and 52-ml oral suspen-
sion (12 mg/ml) 
(b) Oseltamivir Farmanguinhos – 75-mg capsule
(c) Oseltamivir HC – 50-ml oral suspension (15 mg/ml)
8. PREVENTION
Until now, no vaccine has been commercially available 
to protect against novel H1N1 virus, although there are 
everyday actions known to prevent the spread of infection, 
such as:61 
·	 Wash your hands often with soap and water. Alcohol-
based hand cleaners are also effective.
·	 Try to avoid close contact with sick people.
·	 Cover your nose and mouth with a tissue when you 
cough or sneeze.
·	 Stay home if you are sick for 7 days after your symptoms 
begin or until you have been symptom-free for 24 hours.
·	 Follow public health advice regarding school closures, 
avoid crowds.
9. CARE OF PATIENTS WITH CONFIRMED, SUS-
PECTED, OR PROBABLE INFECTION WITH THE 
NOVEL VIRUS INFLUENZA A (H1/N1)
Health care professionals must use the following 
personal protective equipment62:
a)  A surgical mask when the professional is working at a 
distance of less than1 meter from the patients, in proce-
dures without aerosol production.
b)  Special clothes to avoid contact with blood and fluids.
c)  A N95 mask, protective glasses, and gloves in procedures 
with aerosol production, such as intubation, secretion 
manipulation, and autopsies.
10. HC “BUNDLES” FOR NOVEL INFLUENZA A 
(H1N1) INFECTION
As already mentioned, as a reference center for H1N1 
infection, the Hospital das Clínicas da Universidade de São 
Paulo created the “Cabinet Crisis” with the objectives of 
implementing “bundles” for control of S-OIV infection, 
a group of interventions to obtain better outcomes in the 
management of this disease. We adopted some measures to 
obtain continuous and everyday information on the H1N1 
infection, to implement actions to control the pandemics and 
to evaluate the impact of these interventions such as: 
1.  Periodical meetings among healthcare professionals from 
all institutions – directors, professors, epidemiologists, 
infectologists, intensive care physicians – to discuss new 
data and information about the disease
2.  Continuous local Epidemiologic Surveillance to collect 
and analyze the data to assess the impact of the virus and 
determine the groups at an increased risk of complica-
tions.
3.  Information for all professionals and patients about the 
infection, symptoms, diagnosis, and prevention.
4.  Availability of a real time RT-PCR for novel influenza A 
(H1N1) virus in admitted patients.
5.  Reduction of daily visits of families to the hospital.
6.  Implementation of hygienic measures: alcohol-based 
hand cleaner, gloves, masks.
7.  Internet published recommendations on the management 
of infection (www.hcnet.usp.br)
8.  Specific units for the care of patients with suspected or 
confirmed S-OIV infection including emergency room 
attending, regular ward and specialized intensive care 
units.
9.  Guidance for the staff and coworkers to limit contact 
with other people when symptoms are present.
10. Risk groups specialized protocols of care: pregnant 
women, children, immunocompromised patients, and 
chronic diseases.
11. Immediate availability of antiviral therapy.
In the last weeks, we could observe a significant 
reduction in the incidence and mortality of novel influenza A 
(H1N1) infection in São Paulo and in Hospital das Clínicas. 
We suppose that an association of factors contribute to these 
numbers including a global actions plan, the continuous 
epidemiologic monitoring and the acquired expertise to 
diagnosis and adequate treatment of patients. We wish to 
maintain all the adopted measures in Hospital das Clínicas 
with the ongoing objective of obtain better outcomes in 
the management of novel influenza A (H1N1) infection. 
With the accumulating experience and groups of study, we 
hope to contribute continuously with information regarding 
epidemiology, pathogenesis and clinical aspects of this 
pandemics.
11. CONCLUSIONS AND PERSPECTIVES
The 2009 pandemic novel influenza A (H1N1) infection 
continues to spread globally and displays the complexity 
of preexisting viruses, which become highly transmissible 
through genetic mutations and reassortments. In less than 1023
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200 days of known disease in humans, we learned that the 
replication competence and virulence of the novel H1N1 
virus enable it to cause severe clinical presentations and 
death. As a consequence of this outbreak, the world learned 
the value of nonpharmacologic interventions, which can 
save many lives. A vaccine is expected as a potential control 
measure for the pandemic.63 In the Hospital das Clínicas da 
Universidade de São Paulo, a “Cabinet Crisis” was created to 
implement a group of interventions to obtain better outcomes 
in the management of H1N1 infection. 
In our opinion, to control this pandemic, global actions 
are required without a geographic barrier. More studies are 
needed in zoonotic virology to allow a better understanding 
concerning the pathogenesis and epidemiologic aspects of 
the new viruses to prevent emergent diseases. 
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